Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

US pharma giant Pfizer will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative ...

Shares of Arvinas tumbled 53% to $8.30 on March 11 after it reported results from the Veritac-2 Phase 3 trial of vepdegestrant. Arvinas and Pfizer have said the results were positive and that the ...

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...

Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology firm’s decision to re ...

Reported positive topline data for VERITAC-2, the Phase 3 pivotal 2L+ trial of monotherapy vepdegestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 ...

– Presented first-in-human data for the Company’s first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – ...

This guide shares all working scripts, including Sharkbite 2 Pastebin scripts, that players can use to get different auto and god mode features. Sharkbite 2 is a PvP experience on the Roblox platform ...

In January 2025, the US FDA approved DATROWAY (for unresectable or metastatic HR+, HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy ...